ALT 0 3 0 3 B-clinical_variable
( 4 5 4 5 I-clinical_variable
SGPT 5 9 5 9 I-clinical_variable
) 9 10 9 10 I-clinical_variable
less 11 15 11 15 O
than 16 20 16 20 O
or 21 23 21 23 O
equal 24 29 24 29 O
to 30 32 30 32 O
3.0 33 36 33 36 B-upper_bound
times 37 42 37 42 I-upper_bound
ULN 43 46 43 46 I-upper_bound

Age 0 3 47 50 B-age
> 4 5 51 52 O
18 5 7 52 54 B-lower_bound

Albumin 0 7 55 62 B-clinical_variable
> 8 9 63 64 O
2 10 11 65 66 B-lower_bound
g 12 13 67 68 I-lower_bound
/ 13 14 68 69 I-lower_bound
dL 14 16 69 71 I-lower_bound

Aspirin 0 7 72 79 B-treatment
or 8 10 80 82 O
salicylate 11 21 83 93 B-treatment
- 21 22 93 94 I-treatment
containing 22 32 94 104 I-treatment
products 33 41 105 113 I-treatment
, 41 42 113 114 O
which 43 48 115 120 O
may 49 52 121 124 O
increase 53 61 125 133 O
risk 62 66 134 138 O
of 67 69 139 141 O
hemorrhage 70 80 142 152 B-chronic_disease

At 0 2 153 155 O
least 3 8 156 161 O
3 9 10 162 163 B-lower_bound
half 11 15 164 168 O
- 15 16 168 169 O
lives 16 21 169 174 O
must 22 26 175 179 O
have 27 31 180 184 O
elapsed 32 39 185 192 O
since 40 45 193 198 O
monoclonal 46 56 199 209 B-treatment
antibody 57 65 210 218 I-treatment
treatment 66 75 219 228 I-treatment

At 0 2 229 231 O
least 3 8 232 237 O
six 9 12 238 241 B-lower_bound
weeks 13 18 242 247 I-lower_bound
must 19 23 248 252 O
have 24 28 253 257 O
elapsed 29 36 258 265 O
between 37 44 266 273 O
mitomycin 45 54 274 283 B-treatment
C 55 56 284 285 I-treatment
or 57 59 286 288 O
nitrosourea 60 71 289 300 B-treatment
treatment 72 81 301 310 I-treatment

Bilirubin 0 9 311 320 B-clinical_variable
( 10 11 321 322 I-clinical_variable
total 11 16 322 327 I-clinical_variable
) 16 17 327 328 I-clinical_variable
< 18 19 329 330 O
1.5 20 23 331 334 B-upper_bound
times 24 29 335 340 I-upper_bound
upper 30 35 341 346 I-upper_bound
limit 36 41 347 352 I-upper_bound
of 42 44 353 355 I-upper_bound
normal 45 51 356 362 I-upper_bound
( 52 53 363 364 I-upper_bound
ULN 53 56 364 367 I-upper_bound
) 56 57 367 368 I-upper_bound

Cardiac 0 7 369 376 O
Function 8 16 377 385 O
: 16 17 385 386 O
Left 18 22 387 391 B-clinical_variable
ventricular 23 34 392 403 I-clinical_variable
ejection 35 43 404 412 I-clinical_variable
fraction 44 52 413 421 I-clinical_variable
( 53 54 422 423 I-clinical_variable
EF 54 56 423 425 I-clinical_variable
) 56 57 425 426 I-clinical_variable
> 58 59 427 428 O
40 59 61 428 430 B-lower_bound
% 61 62 430 431 I-lower_bound
by 63 65 432 434 O
Echocardiogram 66 80 435 449 B-treatment
, 80 81 449 450 O
MUGA 82 86 451 455 B-treatment
, 86 87 455 456 O
or 88 90 457 459 O
cardiac 91 98 460 467 B-treatment
MR 99 101 468 470 I-treatment

Clinically 0 10 471 481 O
significant 11 22 482 493 O
systemic 23 31 494 502 O
illness 32 39 503 510 O
( 40 41 511 512 O
e.g. 41 45 512 516 O
serious 46 53 517 524 O
active 54 60 525 531 B-chronic_disease
infections 61 71 532 542 I-chronic_disease
or 72 74 543 545 O
significant 75 86 546 557 O
cardiac 87 94 558 565 B-chronic_disease
, 94 95 565 566 O
pulmonary 96 105 567 576 B-chronic_disease
, 105 106 576 577 O
hepatic 107 114 578 585 B-chronic_disease
or 115 117 586 588 O
other 118 123 589 594 O
organ 124 129 595 600 B-chronic_disease
dysfunction 130 141 601 612 I-chronic_disease
) 141 142 612 613 O
, 142 143 613 614 O
that 144 148 615 619 O
in 149 151 620 622 O
the 152 155 623 626 O
judgment 156 164 627 635 O
of 165 167 636 638 O
the 168 171 639 642 O
PI 172 174 643 645 O
would 175 180 646 651 O
compromise 181 191 652 662 O
the 192 195 663 666 O
patient 196 203 667 674 O
s 204 205 675 676 O
ability 206 213 677 684 O
to 214 216 685 687 O
tolerate 217 225 688 696 O
protocol 226 234 697 705 O
therapy 235 242 706 713 B-treatment
or 243 245 714 716 O
significantly 246 259 717 730 O
increase 260 268 731 739 O
the 269 272 740 743 O
risk 273 277 744 748 O
of 278 280 749 751 O
complications 281 294 752 765 O

Clopidogrel 0 11 766 777 B-treatment

Creatinine 0 10 778 788 B-clinical_variable
within 11 17 789 795 O
normal 18 24 796 802 B-clinical_variable
institutional 25 38 803 816 I-clinical_variable
limits 39 45 817 823 I-clinical_variable
or 46 48 824 826 O
creatinine 49 59 827 837 B-clinical_variable
clearance 60 69 838 847 I-clinical_variable
greater 70 77 848 855 O
than 78 82 856 860 O
or 83 85 861 863 O
equal 86 91 864 869 O
to 92 94 870 872 O
60 95 97 873 875 B-lower_bound
mL 98 100 876 878 I-lower_bound
/ 100 101 878 879 I-lower_bound
min/1.73 101 109 879 887 I-lower_bound
m^2 110 113 888 891 I-lower_bound
for 114 117 892 895 O
patients 118 126 896 904 O
with 127 131 905 909 O
creatinine 132 142 910 920 B-clinical_variable
levels 143 149 921 927 I-clinical_variable
above 150 155 928 933 O
institutional 156 169 934 947 B-clinical_variable
normal 170 176 948 954 I-clinical_variable

DLCO 0 4 955 959 B-clinical_variable
, 4 5 959 960 O
< 6 7 961 962 O
30 8 10 963 965 B-upper_bound
% 10 11 965 966 I-upper_bound
predicted 12 21 967 976 O
( 22 23 977 978 O
post 23 27 978 982 B-treatment
- 27 28 982 983 I-treatment
bronchodilator 28 42 983 997 I-treatment
) 42 43 997 998 O

Dextran 0 7 999 1006 B-treatment

Dipyridamole 0 12 1007 1019 B-treatment

Disease 0 7 1020 1027 O
amenable 8 16 1028 1036 O
to 17 19 1037 1039 O
biopsy 20 26 1040 1046 B-treatment
via 27 30 1047 1050 I-treatment
percutaneous 31 43 1051 1063 I-treatment
approach 44 52 1064 1072 O
or 53 55 1073 1075 O
other 56 61 1076 1081 O
minimally 62 71 1082 1091 B-treatment
invasive 72 80 1092 1100 I-treatment
procedures 81 91 1101 1111 I-treatment
such 92 96 1112 1116 O
as 97 99 1117 1119 O
thoracoscopy 100 112 1120 1132 B-treatment
, 112 113 1132 1133 O
bronchoscopy 114 126 1134 1146 B-treatment
, 126 127 1146 1147 O
laparoscopy 128 139 1148 1159 B-treatment
, 139 140 1159 1160 O
or 141 143 1161 1163 O
GI 144 146 1164 1166 B-treatment
endoscopy 147 156 1167 1176 I-treatment

ECOG 0 4 1177 1181 B-clinical_variable
status 5 11 1182 1188 I-clinical_variable
0 12 13 1189 1190 B-lower_bound
- 13 14 1190 1191 O
2 14 15 1191 1192 B-upper_bound

FEV 0 3 1193 1196 B-clinical_variable
, 3 4 1196 1197 O
< 5 6 1198 1199 O
30 7 9 1200 1202 B-upper_bound
% 9 10 1202 1203 I-upper_bound
predicted 11 20 1204 1213 O

Hemoglobin 0 10 1214 1224 B-clinical_variable
greater 11 18 1225 1232 O
than 19 23 1233 1237 O
or 24 26 1238 1240 O
equal 27 32 1241 1246 O
to 33 35 1247 1249 O
8 36 37 1250 1251 B-lower_bound
g 38 39 1252 1253 I-lower_bound
/ 39 40 1253 1254 I-lower_bound
dL 40 42 1254 1256 I-lower_bound
( 43 44 1257 1258 O
PRBC 44 48 1258 1262 B-treatment
transfusions 49 61 1263 1275 I-treatment
permitted 62 71 1276 1285 O
) 71 72 1285 1286 O

Hepatic 0 7 1287 1294 B-treatment
Function 8 16 1295 1303 I-treatment

Hypersensitivity 0 16 1304 1320 O
to 17 19 1321 1323 O
mithramycin 20 31 1324 1335 B-allergy_name

Normal 0 6 1336 1342 O
ionized 7 14 1343 1350 O
calcium 15 22 1351 1358 O
, 22 23 1358 1359 O
magnesium 24 33 1360 1369 O
and 34 37 1370 1373 O
phosphorus 38 48 1374 1384 O
( 49 50 1385 1386 O
can 50 53 1386 1389 O
be 54 56 1390 1392 O
on 57 59 1393 1395 O
oral 60 64 1396 1400 B-treatment
supplementation 65 80 1401 1416 I-treatment
) 80 81 1416 1417 O

Oxygen 0 6 1418 1424 B-clinical_variable
saturation 7 17 1425 1435 I-clinical_variable
greater 18 25 1436 1443 O
than 26 30 1444 1448 O
92 31 33 1449 1451 B-lower_bound
% 33 34 1451 1452 I-lower_bound
on 35 37 1453 1455 O
room 38 42 1456 1460 O
air 43 46 1461 1464 O

PT 0 2 1465 1467 B-clinical_variable
/ 2 3 1467 1468 I-clinical_variable
PTT 3 6 1468 1471 I-clinical_variable
within 7 13 1472 1478 O
normal 14 20 1479 1485 O
limits 21 27 1486 1492 O

Patients 0 8 1493 1501 O
may 9 12 1502 1505 O
have 13 17 1506 1510 O
received 18 26 1511 1519 O
localized 27 36 1520 1529 O
radiation 37 46 1530 1539 B-treatment
therapy 47 54 1540 1547 I-treatment
to 55 57 1548 1550 O
non 58 61 1551 1554 O
- 61 62 1554 1555 O
target 62 68 1555 1561 O
lesions 69 76 1562 1569 O
provided 77 85 1570 1578 O
that 86 90 1579 1583 O
the 91 94 1584 1587 O
radiotherapy 95 107 1588 1600 B-treatment
is 108 110 1601 1603 O
completed 111 120 1604 1613 O
14 121 123 1614 1616 B-upper_bound
days 124 128 1617 1621 I-upper_bound
prior 129 134 1622 1627 I-upper_bound
to 135 137 1628 1630 O
commencing 138 148 1631 1641 O
therapy 149 156 1642 1649 O
, 156 157 1649 1650 O
and 158 161 1651 1654 O
the 162 165 1655 1658 O
patient 166 173 1659 1666 O
has 174 177 1667 1670 O
recovered 178 187 1671 1680 O
from 188 192 1681 1685 O
any 193 196 1686 1689 O
toxicity 197 205 1690 1698 O

Patients 0 8 1699 1707 O
must 9 13 1708 1712 O
be 14 16 1713 1715 O
willing 17 24 1716 1723 O
to 25 27 1724 1726 O
undergo 28 35 1727 1734 O
2 36 37 1735 1736 O
tumor 38 43 1737 1742 B-cancer
biopsies 44 52 1743 1751 B-treatment

Patients 0 8 1752 1760 O
must 9 13 1761 1765 O
have 14 18 1766 1770 O
had 19 22 1771 1774 O
no 23 25 1775 1777 O
chemotherapy 26 38 1778 1790 B-treatment
, 38 39 1790 1791 O
biologic 40 48 1792 1800 B-treatment
therapy 49 56 1801 1808 I-treatment
, 56 57 1808 1809 O
or 58 60 1810 1812 O
radiation 61 70 1813 1822 B-treatment
therapy 71 78 1823 1830 I-treatment
for 79 82 1831 1834 O
their 83 88 1835 1840 O
malignancy 89 99 1841 1851 B-cancer
for 100 103 1852 1855 O
at 104 106 1856 1858 O
least 107 112 1859 1864 O
30 113 115 1865 1867 B-lower_bound
days 116 120 1868 1872 I-lower_bound
prior 121 126 1873 1878 I-lower_bound
to 127 129 1879 1881 O
treatment 130 139 1882 1891 B-treatment

Patients 0 8 1892 1900 O
must 9 13 1901 1905 O
have 14 18 1906 1910 O
had 19 22 1911 1914 O
or 23 25 1915 1917 O
refused 26 33 1918 1925 O
first 34 39 1926 1931 O
- 39 40 1931 1932 O
line 40 44 1932 1936 O
standard 45 53 1937 1945 O
chemotherapy 54 66 1946 1958 B-treatment
for 67 70 1959 1962 O
their 71 76 1963 1968 O
inoperable 77 87 1969 1979 B-cancer
malignancies 88 100 1980 1992 I-cancer

Patients 0 8 1993 2001 O
on 9 11 2002 2004 O
therapeutic 12 23 2005 2016 B-treatment
anticoagulation 24 39 2017 2032 I-treatment

Patients 0 8 2033 2041 O
who 9 12 2042 2045 O
are 13 16 2046 2049 O
concurrently 17 29 2050 2062 O
receiving 30 39 2063 2072 O
or 40 42 2073 2075 O
requiring 43 52 2076 2085 O
any 53 56 2086 2089 O
of 57 59 2090 2092 O
the 60 63 2093 2096 O
following 64 73 2097 2106 O
agents 74 80 2107 2113 O
, 80 81 2113 2114 O
which 82 87 2115 2120 O
may 88 91 2121 2124 O
increase 92 100 2125 2133 O
the 101 104 2134 2137 O
risk 105 109 2138 2142 O
for 110 113 2143 2146 O
mithramycin 114 125 2147 2158 B-treatment
related 126 133 2159 2166 O
toxicities 134 144 2167 2177 O
, 144 145 2177 2178 O
such 146 150 2179 2183 O
as 151 153 2184 2186 O
hemorrhage 154 164 2187 2197 B-chronic_disease

Patients 0 8 2198 2206 O
with 9 13 2207 2211 O
ABCB4 14 19 2212 2217 B-treatment
, 19 20 2217 2218 O
ABCB11 21 27 2219 2225 B-treatment
, 27 28 2225 2226 O
RALBP 29 34 2227 2232 B-treatment
or 35 37 2233 2235 O
CYP851 38 44 2236 2242 B-treatment
genotypes 45 54 2243 2252 O
associated 55 65 2253 2263 O
with 66 70 2264 2268 O
mithramycin 71 82 2269 2280 B-treatment
- 82 83 2280 2281 I-treatment
mediated 83 91 2281 2289 I-treatment
hepatotoxicity 92 106 2290 2304 I-treatment

Patients 0 8 2305 2313 O
with 9 13 2314 2318 O
any 14 17 2319 2322 O
of 18 20 2323 2325 O
the 21 24 2326 2329 O
following 25 34 2330 2339 O
pulmonary 35 44 2340 2349 B-chronic_disease
function 45 53 2350 2358 I-chronic_disease
abnormalities 54 67 2359 2372 I-chronic_disease

Patients 0 8 2373 2381 O
with 9 13 2382 2386 O
cerebral 14 22 2387 2395 B-cancer
metastases 23 33 2396 2406 I-cancer

Patients 0 8 2407 2415 O
with 9 13 2416 2420 O
evidence 14 22 2421 2429 O
of 23 25 2430 2432 O
active 26 32 2433 2439 B-chronic_disease
bleeding 33 41 2440 2448 I-chronic_disease
, 41 42 2448 2449 O
intratumoral 43 55 2450 2462 B-chronic_disease
hemorrhage 56 66 2463 2473 I-chronic_disease
or 67 69 2474 2476 O
history 70 77 2477 2484 O
of 78 80 2485 2487 O
bleeding 81 89 2488 2496 B-chronic_disease
diatheses 90 99 2497 2506 I-chronic_disease

Patients 0 8 2507 2515 O
with 9 13 2516 2520 O
history 14 21 2521 2528 O
of 22 24 2529 2531 O
HIV 25 28 2532 2535 B-chronic_disease
, 28 29 2535 2536 O
HBV 30 33 2537 2540 B-chronic_disease
or 34 36 2541 2543 O
HCV 37 40 2544 2547 B-chronic_disease
due 41 44 2548 2551 O
to 45 47 2552 2554 O
potentially 48 59 2555 2566 O
increased 60 69 2567 2576 O
risk 70 74 2577 2581 O
of 75 77 2582 2584 O
mithramycin 78 89 2585 2596 O
toxicity 90 98 2597 2605 O
in 99 101 2606 2608 O
this 102 106 2609 2613 O
population 107 117 2614 2624 O

Patients 0 8 2625 2633 O
with 9 13 2634 2638 O
measurable 14 24 2639 2649 O
inoperable 25 35 2650 2660 O
, 35 36 2660 2661 O
histologically 37 51 2662 2676 O
confirmed 52 61 2677 2686 O
primary 62 69 2687 2694 B-cancer
lung 70 74 2695 2699 I-cancer
and 75 78 2700 2703 O
esophageal 79 89 2704 2714 B-cancer
carcinomas 90 100 2715 2725 I-cancer
, 100 101 2725 2726 O
thymic 102 108 2727 2733 B-cancer
neoplasms 109 118 2734 2743 I-cancer
, 118 119 2743 2744 O
germ 120 124 2745 2749 B-cancer
cell 125 129 2750 2754 I-cancer
tumors 130 136 2755 2761 I-cancer
, 136 137 2761 2762 O
malignant 138 147 2763 2772 B-cancer
pleural 148 155 2773 2780 I-cancer
mesotheliomas 156 169 2781 2794 I-cancer
or 170 172 2795 2797 O
chest 173 178 2798 2803 B-cancer
wall 179 183 2804 2808 I-cancer
sarcomas 184 192 2809 2817 I-cancer

Peripheral 0 10 2818 2828 B-clinical_variable
ANC 11 14 2829 2832 I-clinical_variable
greater 15 22 2833 2840 O
than 23 27 2841 2845 O
or 28 30 2846 2848 O
equal 31 36 2849 2854 O
to 37 39 2855 2857 O
1500 40 44 2858 2862 B-lower_bound
/ 44 45 2862 2863 I-lower_bound
mm^3 45 49 2863 2867 I-lower_bound

Platelets 0 9 2868 2877 B-clinical_variable
greater 10 17 2878 2885 O
than 18 22 2886 2890 O
or 23 25 2891 2893 O
equal 26 31 2894 2899 O
to 32 34 2900 2902 O
100,000/ 35 43 2903 2911 B-lower_bound
mm^3 44 48 2912 2916 I-lower_bound
( 49 50 2917 2918 O
transfusion 50 61 2918 2929 B-treatment
independent 62 73 2930 2941 O
) 73 74 2941 2942 O

Sulfinpyrazone 0 14 2943 2957 B-treatment

Thrombolytic 0 12 2958 2970 B-treatment
agents 13 19 2971 2977 I-treatment

Valproic 0 8 2978 2986 B-treatment
acid 9 13 2987 2991 I-treatment

patients 0 8 2992 3000 O
with 9 13 3001 3005 O
gastric 14 21 3006 3013 B-cancer
, 21 22 3013 3014 O
colorectal 23 33 3015 3025 B-cancer
or 34 36 3026 3028 O
renal 37 42 3029 3034 B-cancer
cancers 43 50 3035 3042 I-cancer
and 51 54 3043 3046 O
sarcomas 55 63 3047 3055 B-cancer
metastatic 64 74 3056 3066 I-cancer
to 75 77 3067 3069 I-cancer
the 78 81 3070 3073 I-cancer
thorax 82 88 3074 3080 I-cancer

pregnant 0 8 3081 3089 B-pregnancy
females 9 16 3090 3097 B-gender
( 17 18 3098 3099 O
due 18 21 3099 3102 O
to 22 24 3103 3105 O
risk 25 29 3106 3110 O
to 30 32 3111 3113 O
fetus 33 38 3114 3119 O
or 39 41 3120 3122 O
newborn 42 49 3123 3130 O
, 49 50 3130 3131 O
and 51 54 3132 3135 O
lack 55 59 3136 3140 O
of 60 62 3141 3143 O
testing 63 70 3144 3151 O
for 71 74 3152 3155 O
excretion 75 84 3156 3165 O
in 85 87 3166 3168 O
breast 88 94 3169 3175 O
milk 95 99 3176 3180 O
) 99 100 3180 3181 O

prophylactic 0 12 3182 3194 B-treatment
anticoagulation 13 28 3195 3210 I-treatment
( 29 30 3211 3212 O
i.e. 30 34 3212 3216 O
intralumenal 35 47 3217 3229 B-treatment
heparin 48 55 3230 3237 I-treatment
) 55 56 3237 3238 O
for 57 60 3239 3242 O
venous 61 67 3243 3249 O
or 68 70 3250 3252 O
arterial 71 79 3253 3261 O
access 80 86 3262 3268 O
devices 87 94 3269 3276 O

specifically 0 12 3277 3289 O
occurring 13 22 3290 3299 O
as 23 25 3300 3302 O
an 26 28 3303 3305 O
isolated 29 37 3306 3314 O
incident 38 46 3315 3323 O
during 47 53 3324 3330 O
reversible 54 64 3331 3341 O
chemotherapy 65 77 3342 3354 B-treatment
induced 78 85 3355 3362 O
thrombocytopenia 86 102 3363 3379 B-chronic_disease

